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The median disease duration of Hurley I patients was 9 years (IQR 
4–18). Both Hurley II and Hurley III patients developed their current 
Hurley stage 6 years ago (p = 0.633) and the two groups reached their 
current stage in a median time period of 6 and 5 years (IQR 3–12 and 
2–12, respectively). However, the progression from Hurley I to Hur-
ley II was significantly shorter in current Hurley III patients with a 
median time period of 3 years (IQR 1–5). Moreover, the progression 
from Hurley II to Hurley III was even faster at 2 years (IQR 1–6). The 
progression time from Hurley I to Hurley II in current Hurley II pa-
tients was significantly shorter compared with the disease duration 
in Hurley I patients (p = 0.038). The time course of disease progres-
sion with respect to severity is visualized in Figure 1.
To our knowledge, this study is the most detailed report on dis-
ease progression rates in HS. Previously, Kromann et al. [5] studied 
long-term follow-up of 121 HS patients and reported a question-
naire-based remission in 39%, improvement in 32%, unchanged 
severity in 21%, and worsening in 9% of patients after an average 
period of 22 years. In addition, von der Werth et al. [6] reported 
that HS patients reached their maximum disease activity after a 
mean disease duration of 6.4 years. However, disease severity was 
not specified. Our results regarding time to maximum disease are 
comparable. The fact that stage I and II patients have stationary 
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Hidradenitis suppurativa (HS) is a chronic, autoinflammatory 
skin disease [1]. HS severity can be classified into three stages ac-
cording to Hurley: Hurley I (45.5% of the patients), Hurley II 
(41.5% of the patients), and Hurley III (13.0% of the patients) (Ta-
ble 1) [2, 3]. If progression to a more severe Hurley stage takes 
place, it is considered irreversible. Even though it is of high clinical 
relevance, there is currently no information available on the time 
course of disease progression through these stages. Therefore, we 
retrospectively studied the disease progression rate.
In 2017, all consecutive HS patients were asked to fill out a su-
pervised questionnaire regarding their disease progression, with 
the current Hurley stage classified by a dermatologist. Photo-
graphs, validated for self-assessing the Hurley stage [4], with an 
oral explanation, were used to support patients in recalling the 
time path of disease progression to each consecutive Hurley stage. 
A two-sided alpha of < 0.05 was considered to be statistically sig-
nificant. This survey was approved by the medical ethics commit-
tee of the Erasmus Medical Centre.
A total of 225 patients completed the questionnaire: 77 (34.2%) 
Hurley I, 98 (43.6%) Hurley II, and 50 (22.2%) Hurley III patients. 
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Table 1. Hurley severity staging
Hurley stage
I Abscess formation, single or multiple, without sinus tracts 
and cicatrization
II Recurrent abscesses with tract formation and cicatrization, 
single or multiple, widely separated lesions
III Diffuse or near-diffuse involvement, or multiple 
interconnected tracts and abscesses across the entire area 
Fig. 1. Disease progression of hidradenitis 
suppurativa patients.
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disease severity for a median of 9 and 6 years, respectively, implies 
that these patients are unlikely to progress to higher stages. This 
strengthens the validity of the found progression rates.
Nonetheless, our results could be affected by recall bias. How-
ever, we argue that a prospective observational study may be dif-
ficult due to ethical and practical reasons.
In conclusion, patients with current Hurley III HS had a quick-
er and more aggressive disease course compared with patients with 
current Hurley II HS. This indicates that a relatively rapid disease 
progression from Hurley I to Hurley II is a predictive factor to de-
velop Hurley III HS, and therefore a sign of a poor prognosis. 
These findings stress the relevance of early diagnosis and adequate 
treatment and follow-up in early stages of HS.
Key Message
Hurley III hidradenitis suppurativa has an aggressive disease 
course.
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